

REMARKS/ARGUMENTS

I. ELECTION

This responds to the Restriction Requirement, dated 2 July 2007. In response to the Restriction Requirement, Applicant elects Group I, claims 1-7, 8, 21-30 (in part as it relates to SEQ ID NO: 1-2; 2 being generic to 1) drawn to an SH3 domain peptide of SEQ ID NO: 1-2 for examination, without traverse. *See* Restriction Requirement of 2 July 2007, paragraph 1 on page 2.

Applicant believes the Examiner intended Group XXXIII, not Group XXII, in paragraph 1 on page 2 of the Restriction Requirement, as the Examiner continued to Group XXXIV in the next line. Clarification is respectfully requested.

II. SUPPORT FOR NEW CLAIMS

Applicant has canceled claims 1-24 and has amended claims 25, 28 and 30. Applicant has also introduced new claims 31-36. Support for these new claims can be found throughout the specification and originally presented claims. Specifically, support for claims 31-36 can be found in at least originally presented claims 8-16 and 25-30 of U.S. Published Application No. 2005/0106695. Accordingly, no new matter has been introduced by way of these new claims. Upon entry of the claim listing, claims 25-36 will be pending.


AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Attorney Docket No.: Q102469

U.S. Application No.: 10/500,804

Applicant believes that the present claims are now in condition for allowance. Should the Examiner believe that further discussion of any remaining issues would advance the prosecution, he or she is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,



Todd B. Buck, Ph.D.

Registration No. 48,574

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: 1 October, 2007